Large-scale transient transfection of suspension mammalian cells for VLP production

Methods in Molecular Biology

Volumn 1674, Issue , 2018, Pages 117-127

  Cervera, Laura ^a   Kamen, Amine A ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Bioreactor; Mammalian cells; Suspension culture; Transient transfection; VLP production

Indexed keywords

DISSOLVED OXYGEN; FLUORESCENT DYE; PLASMID DNA; POLYETHYLENEIMINE; REAGENT; BIOLOGICAL PRODUCT; OXYGEN;

BIOREACTOR; CELL GROWTH; CELL VIABILITY; COMPLEX FORMATION; EVALUATION STUDY; FLOW CYTOMETRY; HEK293 CELL LINE; IN VITRO STUDY; LARGE SCALE PRODUCTION; MAMMAL CELL; METHODOLOGY; NONHUMAN; ONLINE MONITORING; PH; REPRODUCIBILITY; SUSPENSION CELL CULTURE; TRANSIENT TRANSFECTION; VIRUS LIKE AGENT; ANIMAL; CELL CULTURE TECHNIQUE; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; GENETIC TRANSFECTION; HUMAN; MAMMAL; METABOLISM; PHYSIOLOGY; PLASMID; PROCEDURES; SUSPENSION;

ANIMALS; BIOLOGICAL PRODUCTS; BIOREACTORS; CELL CULTURE TECHNIQUES; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; HEK293 CELLS; HUMANS; HYDROGEN-ION CONCENTRATION; MAMMALS; OXYGEN; PLASMIDS; SUSPENSIONS; TRANSFECTION;

EID: 85029714091     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4939-7312-5_10     Document Type: Chapter

References (39)

1. Chahal PS, Schulze E, Tran R et al (2014) Production of adeno-associated virus (AAV) serotypes by transient transfection of HEK293 cell suspension cultures for gene delivery. J Virol Methods 196:163–173
2. Meissner P, Pick H, Kulangara A et al (2001) Transient gene expression: recombinant protein production with suspension-adapted HEK293-EBNA cells. Biotechnol Bioeng 75:197–203
3. Jordan M, Schallhorn A, Wurm FM (1996) Transfecting mammalian cells: optimization of critical parameters affecting calcium-phosphate precipitate formation. Nucleic Acids Res 24:596–601
4. Geisse S (2009) Reflections on more than 10 years of TGE approaches. Protein Expr Purif 64:99–107
5. Jordan M, Wurm F (2004) Transfection of adherent and suspended cells by calcium phosphate. Methods 33:136–143
6. Tait AS, Brown CJ, Galbraith DJ et al (2004) Transient production of recombinant proteins by Chinese hamster ovary cells using polyethy-leneimine/DNA complexes in combination with microtubule disrupting anti-mitotic agents. Biotechnol Bioeng 88:707–721
7. Boussif O, Lezoualc’h F, Zanta MA et al (1995) A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci U S A 92:7297–7301
8. Lungwitz U, Breunig M, Blunk T et al (2005) Polyethylenimine-based non-viral gene delivery systems. Eur J Pharm Biopharm 60:247–266
9. Durocher Y, Perret S, Kamen A (2002) High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. Nucleic Acids Res 30:E9
10. Derouazi M, Girard P, Van Tilborgh F et al (2004) Serum-free large-scale transient transfection of CHO cells. Biotechnolo Bioeng 87:537–545
11. Carpentier E, Paris S, Kamen A et al (2007) Limiting factors governing protein expression following polyethylenimine-mediated gene transfer in HEK293-EBNA1 cells. J Biotechnol 128:268–280
12. Baldi L, Muller N, Picasso S et al (2005) Transient gene expression in suspension HEK-293 cells: application to large-scale protein production. Biotechnol Prog 21:148–153
13. Tuvesson O, Uhe C, Rozkov A et al (2008) Development of a generic transient transfection process at 100 L scale. Cytotechnology 56:123–136
14. Backliwal G, Hildinger M, Chenuet S et al (2008) Rational vector design and multi-pathway modulation of HEK 293E cells yield recombinant antibody titers exceeding 1 g/l by transient transfection under serum-free conditions. Nucleic Acids Res 36:e96
15. Ausubel LJ, Hall C, Sharma A et al (2012) Production of CGMP-grade lentiviral vectors. BioProcess Int 10:32–43
16. Cornetta K, Reeves L, Cross S (2008) Production of retroviral vectors for clinical use. Methods Mol Biol 433:17–32
17. Merten OW, Charrier S, Laroudie N et al (2011) Large-scale manufacture and characterization of a lentiviral vector produced for clinical ex vivo gene therapy application. Hum Gene Ther 22:343–356
18. Wright JF (2008) Manufacturing and characterizing AAV-based vectors for use in clinical studies. Gene Ther 15:840–848
19. Wright JF (2009) Transient transfection methods for clinical adeno-associated viral vector production. Hum Gene Ther 20:698–706
20. Ayuso E, Mingozzi F, Bosch F (2010) Production, purification and characterization of adeno-associated vectors. Curr Gene Ther 10:1–14
21. Berzofsky JA, Ahlers JD et al (2004) Progress on new vaccine strategies against chronic viral infections. J Clin Invest 114:450–462
22. Grgacic EVL, Anderson DA (2006) Virus-like particles: passport to immune recognition. Methods 40:60–65
23. Ludwig C, Wagner R (2007) Virus-like particles-universal molecular toolboxes. Curr Opin Biotechnol 18:537–545
24. Noad R, Roy P (2003) Virus-like particles as immunogens. Trends Microbiol 11:438–444
25. Hermida-Matsumoto L, Resh MD (2000) Localization of human immunodeficiency virus type 1 Gag and Env at the plasma membrane by confocal imaging. J Virol 74:8670–8679
26. Zhou W, Bi J, Janson JC et al (2006) Molecular characterization of recombinant Hepatitis B surface antigen from Chinese hamster ovary and Hansenula polymorpha cells by high- performance size exclusion chromatography and multi-angle laser light scattering. J Chromatogr B Analyt Technol Biomed Life Sci 838:71–77
27. Harper DM, Franco EL, Wheeler C et al (2004) Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364:1757–1765
28. Bright RA, Carter DM, Daniluk S et al (2007) Influenza virus-like particles elicit broader immune responses than whole virion inacti-vated influenza virus or recombinant hemagglutinin. Vaccine 25:3871–3878
29. Zhang X, Wang X, Zhao D et al (2011) Design and immunogenicity assessment of HIV-1 virus-like particles as a candidate vaccine. Sci China Life Sci 54:1042–1047
30. Cervera L, Gutiérrez-Granados S, Martínez M et al (2013) Generation of HIV-1 Gag VLPs by transient transfection of HEK 293 suspension cell cultures using an optimized animal-derived component free medium. J Biotechnol 166:152–165
31. Buonaguro L, Tornesello ML, Tagliamonte M et al (2006) Baculovirus-derived human immunodeficiency virus type 1 virus-like particles activate dendritic cells and induce ex vivo T-cell responses. J Virol 80:9134–9143
32. Roldão A, Mellado MCM, Castilho LR et al (2010) Virus-like particles in vaccine development. Expert Rev Vaccines 9:1149–1176
33. Herbst-Kralovetz M, Mason HS, Chen Q (2010) Norwalk virus-like particles as vaccines. Expert Rev Vaccines 9:299–307
34. Vieira HLA, Estêvão C, Roldão A et al (2005) Triple layered rotavirus VLP production: kinetics of vector replication, mRNA stability and recombinant protein production. J Biotechnol 120:72–82
35. Buonaguro L, Buonaguro FM, Tornesello ML et al (2001) High efficient production of Pr55gag virus-like particles expressing multiple HIV-1 epitopes, including a gp120 protein derived from an Ugandan HIV-1 isolate of subtype A. Antiviral Res 49:35–47
36. Gutiérrez-Granados S, Cervera L, Gòdia F et al (2013) Development and validation of a quantitation assay for fluorescently tagged HIV-1 virus-like particles. J Virol Methods 193:85–95
37. Geng ZH, Nudson W, Davis L et al (2007) Optimizing medium for transient transfection. In: Smith R (ed) Cell technology for cell products. Springer Netherlands, Dordrecht
38. Backliwal G, Hildinger M, Hasija V, et al (2008) High-density transfection with HEK-293 cells allows doubling of transient titers and removes need for a priori DNA complex formation with PEI. Biotechnol Bioeng 99:721–727
39. Eibl R, Kaiser S, Lombriser R et al (2010) Disposable bioreactors: the current state-of-the-art and recommended applications in biotechnology. Appl Microbiol Biotechnol 86:41–49